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Soft and ﬂexible poly(ethylene glycol) nanotubes
for local drug delivery†
B. Newland, *‡a,b C. Taplan,a,c D. Pette,a J. Friedrichs,a M. Steinhart, d
W. Wang, e B. Voit,c,f F. P. Seiba,g and C. Werner a
Nanotubes are emerging as promising materials for healthcare
applications but the selection of clinically relevant starting
materials for their synthesis remains largely unexplored. Here we
present, for the ﬁrst time, the synthesis of poly(ethylene glycol)
(PEG) based nanotubes via the photopolymerization of poly(ethyl-
ene glycol) diacrylate and other diacrylate derivatives within the
pores of anodized aluminum oxide templates. Template-assisted
synthesis allowed the manufacture of a diverse set of polymeric
nanotubes with tunable physical characteristics including diameter
(∼200–400 nm) and stiﬀness (405–902 kPa). PEG nanotubes were
subjected to cytotoxicty assessment in cell lines and primary stem
cells and showed excellent cytocompatability (IC50 > 120 μg ml
−1).
Nanotubes were readily drug loaded but released the majority of
the drug over 5 days. Direct administration of drug loaded nano-
tubes to human orthotopic breast tumors substantially reduced
tumor growth and metastasis and outperformed i.v. administration
at the equivalent dose. Overall, this nanotube templating platform
is emerging as a facile route for the manufacture of poly(ethylene
glycol) nanotubes.
Hollow high aspect ratio materials such as nanotubes are an
interesting proposition for sustained drug release due to their
combination of a high surface area to volume (for drug adsorp-
tion/loading) and an internal pore (for filling with drug).1
Carbon nanotubes have been heavily investigated for appli-
cations in gene and drug delivery.2–4 In their pristine form,
without wall functionalization, carbon nanotubes can be
loaded with certain drug molecules such as doxorubicin via
π-stacking.2 However, a range of functionalization strategies
can be pursued to facilitate the loading of specific molecules.
Carbon nanotubes are particularly interesting for intracellular
drug delivery because they have been shown to be taken up by
multiple cell types via energy-independent mechanisms
regardless of the functionalization strategy used.5 However,
this intrinsic ability to pierce the cell membrane can be associ-
ated with cellular toxicity.6 Whilst the toxicity of carbon nano-
tubes is multifactorial (length, rigidity, impurities etc.7), they
are rarely used in their pristine state as they require
functionalization to improve their biocompatibility and stabi-
lity (as a dispersed suspension). Poly(ethylene glycol) (PEG) or
diamino-triethylene glycol polymers are commonly used for
these purposes.8
Our hypothesis was to negate the need for a carbon nano-
tube starting material, instead using PEG as the nanotube
bulk material thus eliminating the need for post modifi-
cations. As PEG can be used to improve the biocompatibility of
nanoparticles,9 we speculated that non-toxic nanotubes could
be produced. Porous anodized aluminum oxide (AAO) has
served as a template for creating nanomaterials composed of
silica,10 carbon,11 DNA,12 proteins,13 and polystyrene14
(reviewed elsewhere15,16). Herein, for the first time, we photo-
polymerize poly(ethylene glycol) diacrylate (PEGDA) and other
diacrylate monomers within the pores of anodized aluminium
oxide templates to create polymer nanotubes. Three diﬀerent
polymer nanotubes (herein termed PEG, Phos and Bisphenol)
were successfully synthesized via the photopolymerization of
three diﬀerent divinyl monomers: poly(ethylene glycol) diacry-
late (PEGDA), bis[2-(methacryloyloxy)ethyl] phosphate and
bisphenol A ethoxylate diacrylate respectively. Precursor solu-
tions containing the divinyl monomer and 2-hydroxy-2-methyl-
propiophenone as a photoinitiator were prepared in acetone
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and added to porous anodized aluminum oxide (AAO) mem-
branes (Scheme 1). Fig. 1 shows the porous structure of the
anodized aluminum oxide template prior to filling with the
precursor solution (average pore diameter of the anodized
aluminum oxide template was 224 nm ± 44 nm (Fig. S1†)).
The monomers were successfully added to the template,
which formed a continuous inner layer on the template pore
wall. They were then polymerized into a crosslinked tube upon
irradiation by UV light and released via template dissolution
(30 minutes in sodium hydroxide17,18) (Raman spectroscopy
shown in Fig. S2†). Partial dissolution of the template
(3 minutes in sodium hydroxide) was also performed to visual-
ize the nanotubes whilst still in the template (Fig. S3†). These
images show the diﬀerence between the upper and lower
surface of the templates indicating that the pore structure is
not constant throughout the template. For this reason, the
monomer solution was added to both sides of the template
during synthesis. Representative SEM images of PEG, Phos
and Bisphenol polymer nanotubes are shown in Fig. 1.
MWCNTs with a diameter close that of the polymer nanotubes
were used in these studies as a comparison material (SEM
image of the MWCNTs is shown in Fig. S4†).
The PEG nanotubes are approximately double the length of
their carbon nanotube counterparts (average length of PEG
nanotubes was 15.4 µm (±11.4 µm) vs. 6.2 µm (±3.0 µm) for
MWCNT) with some PEG nanotubes reaching 60 µm in length
(Fig. S5†). All three polymer nanotube types had a smaller dis-
tribution of diameters than MWCNT (Fig. S6†) with the nano-
tube diameter being dictated by the pore diameter of the ano-
dized aluminum template (average diameter or PEG nanotubes
was 202 nm). MWCNTs showed a large range in diameter
ranging from 60 nm to 800 nm with an average diameter of
164 nm (manufacturer’s diameter range given as 110 nm–
170 nm). Transmission electron microscope (TEM) images of
the four diﬀerent nanotube types are shown in Fig. S7† with
additional higher magnification images of the nanotube ends.
These images also show the regular diameter of the polymer
nanotubes in comparison to the wide variation displayed by
MWCNTs.
Proof of concept experiments showed that we can syn-
thesize PEG nanotubes of two diﬀerent diameters (average
202 nm (±37 nm) and 402 nm (±57 nm)) (Fig. S8†) and
diﬀerent lengths (average 7.5 µm (±3.2 µm) and 30.9 µm
(±19.0 µm)) (Fig. S9†) depending on the type of anodized
aluminum oxide template used.
Representative SEM images (Fig. 1a–c) show that the
diﬀerent polymer nanotubes in their dry state appear to have
diﬀerent morphologies, with PEG and Bisphenol nanotubes
Scheme 1 Schematic depiction of the nanotube synthesis process showing the three monomers used and the simple three-step procedure that
can be used to create a variety of polymer nanotubes.
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being very entangled around each other, in contrast to the
Phos nanotubes that are less curved and not so intertwined;
this suggests that the Phos nanotubes are less flexible than the
others.
We reasoned that this diﬀerence in structure may be due to
the shorter chain length of the bis[2-(methacryloyloxy)ethyl]
phosphate monomer used to make the Phos nanotubes (Mw =
322 Da, 2 PEG units), than the PEGDA monomer used to make
the PEG nanotubes (Mw ∼ 575 Da, 10 PEG units). A shorter
monomer chain length would result in a higher crosslinking
density and therefore a more rigid structure. To analyze the
mechanical properties of the nanotubes, atomic force
microscopy was performed to create force maps, from which
the elastic modulus (Young’s modulus) was determined
(Fig. 1d–f ). Indentation of the nanotube wall, showed that PEG
nanotubes (405 kPa, ±32) were significantly softer than Phos
nanotubes (902 kPa, ±42), with Bisphenol nanotubes in
between (607 kPa, ±79). This data suggests that the choice of
monomer selected to make the nanotubes will not only aﬀect
its chemical composition, but also the mechanical properties
of the polymer nanotubes. MWCNTs were ∼2000 times stiﬀer
(Young’s modulus of 2.07 GPa, ±0.36) showing that the
polymer nanotubes are indeed very soft and flexible.
As an initial screen, to analyze the inherent cytotoxicity of
the polymer nanotubes in direct comparison to MWCNTs,
cells grown in culture were incubated with nanotubes ranging
in concentration from 0 to 120 µg mL−1 for 1 or 3 days. Mouse
fibroblasts (3T3) (Fig. S10†), human mesenchymal stem cells
(MSCs) (Fig. S11†) and human breast epithelial cells
(MCF-10A) (Fig. S12†) were used. No decrease in 3T3 cell viabi-
lity occurred for all nanotube types at any of the concen-
trations tested (Fig. S10a†). Images show no change in cell
morphologies, although the MWCNTs appeared to be aggre-
gated with the cells (Fig. S10b†). MSCs were the most aﬀected
Fig. 1 Nanotube characterization (a) SEM image of a anodized aluminum oxide membrane cut through and tilted to show the upper surface (high
magniﬁcation and non-tilted image shown inset) and pore structure extending through the membrane. (b) A higher magniﬁcation image of PEG
nanotubes, and (c) lower magniﬁcation images of the three diﬀerent polymer nanotubes showing how they are orientated diﬀerently once dry. (d)
Representative AFM force maps, with (e) corresponding height maps (scale bars = 100 nm). (f ) A split axis graph showing that the Phos nanotubes
are stiﬀer than the PEG and Bisphenol nanotubes but are ∼2000 times less stiﬀ than MWCNTs (n = 3, error bars represent ± standard deviation,
* show statistical signiﬁcant diﬀerence from PEG nanotubes (P ≤ 0.05, one way ANOVA)).
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by the nanotubes with a decrease in viability to 77% (Phos),
67% (Bisphenol) and 30% (MWCNT) after three days of incu-
bation at 120 µg mL−1 (Fig. S11†). In these stem cell cultures
Phos nanotubes and MWCNT aggregated at the cell surface.
PEG nanotubes formed an even covering over the cells and
well plate bottom and did not reduce stem cell viability. In a
similar manner to the 3T3 cells, incubation of MCF-10A cells
with nanotubes did not aﬀect their viability for all nanotube
types and concentrations tested (Fig. S12†). The next step was
to assess whether these nanotubes could be used as a local
drug delivery system.
Systemic delivery of anticancer drugs as part of an adjuvant
chemotherapy regime for breast cancer patients is associated
with severe adverse side eﬀects. These eﬀects can be classified
into short term eﬀects such as nausea/emesis, thromboembo-
lism, stomatitis etc., and long term eﬀects such as premature
menopause/infertility, neuropathy and cardiac dysfunction.19
Doxorubicin is commonly used as part of the treatment regime
for both early stage and metastatic breast cancer, but has
severe toxicity issues.20 Local drug delivery strategies represent
a way to enhance the eﬀectiveness of the drug, whilst reducing
its side eﬀects, by releasing a high concentration of the drug
focally to the tumor. Local drug delivery is already in use for a
range of malignancies, and drug delivery devices in develop-
ment take on a range of diﬀerent forms including wafers,
films, nanoparticles, gels and rods (reviewed elsewhere21).
Because tumor resection is common in breast cancer one
could envisage the application of a local drug delivery system
at the surgical site. Such a drug delivery system would ideally
have some of the following characteristics: (a) be injectable
(ease of application), (b) release the drug over an extended
period of time, (c) remain at the injection site (reduce oﬀ-
target eﬀects), (d) be inert and non-toxic, and (e) be bio-
degradable. Such a system could also potentially be used for
preoperative drug delivery to the tumor site or, if proven
eﬀective enough, used instead of systemic drug
administration.22
To assess whether these nanotubes would uptake the che-
motherapeutic drug doxorubicin, we incubated the nanotubes
in an aqueous solution of doxorubicin (100 µg mL−1, drug to
nanotube ratio of 1 : 10 – see ESI† for details) for 24 hours.
Qualitative and quantitative assessment showed that PEG and
Phos nanotubes eﬃciently took up the doxorubicin (Fig. S14†)
(PEG 99.6%, Phos 96.3%, Bisphenol 30.6% and MWCNT
30.0%). We had speculated that the Bisphenol nanotubes may
be a good candidate for loading doxorubicin either via hydro-
phobic interactions or via π-stacking of electrons between the
six-membered rings on both the nanotubes and the doxo-
rubicin molecule; however, less doxorubicin was loaded to the
Bisphenol nanotubes. Instead, it is probable that the negative
charge of the phosphate groups of the Phos nanotubes is a
prominent driving force behind the eﬃcient uptake of doxo-
rubicin, via electrostatic interaction with the primary amine
group on doxorubicin.
Although PEG should have no formal charge, the PEG
nanotubes are perhaps successful in drug loading via the
acquisition of a negative charge during the synthesis process.
The 30 minutes treatment in sodium hydroxide (to dissolve
the anodized aluminum oxide template) would cause hydro-
lysis of some of the PEG chains to from carboxylic acid
groups on the nanotube surfaces (Fig. 2). Analysis of the
degradation of the PEG nanotubes in sodium hydroxide
shows that the nanotubes were completely broken down after
3 hours at room temperature (Fig. 2c). Zeta potential analysis
of the PEG nanotubes showed a negative surface charge,
though this was similar for all types of nanotubes (Fig. S15†)
indicating that the mechanism of drug loading is complex
and may not just be due to electrostatic interaction, but a
combination of driving forces. Interestingly, the MWCNTs
showed the highest rise in surface charge upon loading with
doxorubicin, suggesting that the drug is surface adsorbed,2,23
whereas the polymer nanotubes maybe loading not only by
surface adsorption but also within the pore. One would
expect that the nanotubes might be biodegradable in physio-
logical conditions via ester hydrolysis or ether oxidation.
Long term studies with crosslinked PEGDA hydrogels, using
polyethylene diacrylamide as controls, showed that ester
hydrolysis is the likely mechanism of crosslinked PEGDA
degradation after subcutaneous implantation in the rat.24
Furthermore, the secretome of frustrated phagocytes contain-
ing acid and hydroxyl radicals, could cause oxidative bio-
degradation.25,26 However, caution should be exercised before
extrapolating analysis of PEGDA hydrogels to nanotubes
formed from PEGDA due to diﬀerences in crosslink density
and material size.
Based on the cytotoxicity and loading data only PEG nano-
tubes were examined further while MWCNTs served as a refer-
ence. In order to assess the maximum loading of doxorubicin
to PEG nanotubes, we first defined a dose of doxorubicin that
would be used for in vivo studies. In line with previous work,27
80 µg of doxorubicin per mouse (i.e. two bilateral tumors per
mouse each treated with 40 µg) would be used for systemic
administration, so this value served as the benchmark from
which to determine what mass of nanotubes could uptake this
amount of drug. Fig. S16† shows that a concentration of at
least 4 mg mL−1 is required to fully load the nanotubes with
doxorubicin, indicating that the maximum weight-to-weight
ratio of doxorubicin to nanotube is 0.2 : 1. The release of doxo-
rubicin from nanotubes loaded with either 40 µg of doxo-
rubicin (standard dose used in vivo (henceforth termed “stan-
dard”) which matched the intravenous doxorubicin control
dose) or 80 µg of doxorubicin (highest dose used in vivo hence-
forth termed “high”) was analyzed over a period of 42 days.
The majority of the doxorubicin was released over the first
seven days (28.4 µg for the “standard” group, 51.1 µg for the
“high” group) (Fig. 2d and e). Then, after this period, a further
1.2 µg (“standard” group) or 2.1 µg (“high” group) was
released. To provide context a recent study showed that even a
doxorubicin dose as low as 0.4 µg mL−1 can be extremely toxic
to prostate cancer cell lines grown in vitro,28 so although these
are small amounts released they may still provide therapeutic
benefit. Fig. 2e shows that even after this extended incubation
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time, not all the doxorubicin was released from the nanotubes
(as readily visible from the red doxorubicin-associated color).
These data suggest that the PEG nanotubes not only draw
doxorubicin out of solution more eﬀectively than MWCNT but
also release the drug over a 5-day period.
In order to assess the cytotoxicity of nanotubes in the pres-
ence and absence of loaded doxorubicin two human breast
cancer cell lines were used: estrogen-responsive MCF-7 cells
(Fig. S17†) and highly aggressive triple negative MDA-MB-231
cells (Fig. 3). MCF-7 cells are commonly used for analyzing
drug delivery systems in vitro,29,30 and MDA-MB-231 cells is a
good human metastatic breast cancer model;27,31–33 these were
subsequently used here in an orthotopic breast cancer mouse
model.27,33 MCF-7 cell viability was not aﬀected by unloaded
PEG nanotubes; however, doxorubicin loaded PEG nanotubes
at 60 µg mL−1 reduced cell viability to 71% and 38%
(Fig. S17†) after one day and three days, respectively. The doxo-
rubicin loaded PEG nanotubes were directly compared to a
positive control of freely diﬀusible doxorubicin at a concen-
tration of 4 µg mL−1 which has previously been shown to be
toxic to range of cell types.28
For MDA-MB-231 cells, doxorubicin loaded PEG nanotubes
at a concentration of 60 µg mL−1 reduced their viability to 64%
and 18% after one and three days, respectively (Fig. 3a). Light
microscopy analysis (Fig. 3b) suggested that both the empty
and doxorubicin loaded MWCNTs clustered with the cells,
which is in accordance with the theory that both positive and
negatively charged MWCNTs are capable of cell penetration/
uptake.34 Perhaps the large average diameter of the MWCNTs
in this study limited their inherent toxicity in these cells.
In stark contrast to MWCNTs, for both the MCF-7 and
MDA-MB-231 cell experiments, the PEG nanotubes formed an
Fig. 2 A proposed reaction scheme for the degradation of PEG nanotubes. (a) Ester hydrolysis of crosslinked PEGDA to yield carboxylic acid
groups. (b) A schematic diagram showing the initial change in nanotube charge upon release from the template, and subsequent destruction of the
nanotubes if left in sodium hydroxide. (c) Time lapse light microscopy of the degradation of PEG nanotubes left in 1 molar sodium hydroxide for
3 hours. (d) Doxorubicin loaded PEG nanotubes release the drug for 42 days in vitro, (“standard” = 400 µg mL−1, “high” = 800 µg mL−1 of doxo-
rubicin). (e) Approximately 80–90% of the doxorubicin is released in the ﬁrst seven days, then only a small amount (1.2 µg for standard group or
2.1 µg for high group) was released over the following 35 days (n = 4, error bars represent ± the cumulative standard deviation).
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even layer over the well bottom, emphasizing that these inert
nanotubes should function as a local sustained delivery device
rather than performing direct cell penetration.
To prove the principle that that the PEG nanotubes could
be used for local/sustained drug release we analyzed this
system in an aggressive orthotopic metastatic breast cancer
mouse model. The primary endpoint of this study was to
assess clinical eﬃcacy in mice treated with doxorubicin focally
delivered via PEG nanotubes compared to an equivalent dose
of intravenously administered doxorubicin.
MDA-MB-231 cells expressing the firefly luciferase gene
allowed tumor growth to be monitored via non-invasive bio-
luminescence over time. The ability to image the implanted
cells also allowed us to evaluate a secondary endpoint:
whether treatment with the doxorubicin loaded nanotubes
reduced the extent of metastases. Note that we also included
in this study a “high” dose group where the nanotubes con-
tained twice the amount of doxorubicin as the “standard”
group (therefore also twice the amount as the intravenous
doxorubicin group) (see Fig. 4a for experimental layout).
Tumor cell-associated bioluminescence signals of untreated
and i.v. doxorubicin dosed animals were similar over the 6
weeks study period (Fig. 4b and d). The equivalent amount of
doxorubicin (i.e. 40 µg per tumor) delivered locally via the PEG
nanotubes showed reduced tumor growth compared to the i.v.
doxorubicin group at week 5, which reached statistical signifi-
cance by week 6 (P ≤ 0.01). Increasing the PEG nanotube doxo-
rubicin loading to a dose of 80 μg per tumor (“high” dose)
resulted in a more pronounced eﬀect of the same trend (P ≤
0.001 at week 6, when compared with the i.v. doxorubicin
group). However, the “high” dose of doxorubicin delivered
from the PEG nanotubes was likely outside the therapeutic
Fig. 3 Cytotoxicity of doxorubicin loaded nanotubes with MDA-MB-231 breast cancer cells in vitro. (a) After one day (left hand graph),
MDA-MB-231 cells incubated with either doxorubicin loaded MWCNTs or doxorubicin loaded PEG nanotubes show a signiﬁcant decrease in viability
which is further reduced by day three (as measured via the PrestoBlue assay). All nanotubes were subject to the same loading solutions (80 µg of
doxorubicin per 1 mg of nanotubes (0.08 : 1 ratio)). Positive control is doxorubicin in solution at a concentration of 4 µg mL−1 (b) corresponding light
microscope images of the 60 µg mL−1 nanotube concentration show the eﬀect of the loaded nanotubes on cell morphology (n = 4), error bars rep-
resent ± standard deviation, * represents statistical signiﬁcant diﬀerence to empty PEG nanotubes, (two way ANOVA with Tukey’s multiple compari-
son test (P ≤ 0.05)).
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window and induced toxicity. Therefore, three animals were
euthanized due to ill health (7 and 13 days after initiation of
therapy). We speculate that this could be due to cardiotoxicity,
a well-known side eﬀect of doxorubicin therapy.20,35
Assessment of tumor weight at the end of the study showed
that i.v. doxorubicin dosing reduced the average tumor mass
from 549 mg ± 326 (i.e. control) to 414 mg ± 124 (Fig. 4c).
Local administration of the PEG nanotubes loaded with the
“standard” doxorubicin dose substantially reduced the average
tumor weight (343 mg ± 111). The “high” dose group signifi-
cantly reduced the tumor burden (159 mg ± 64; P ≤ 0.01) com-
pared to untreated controls (Fig. 4c). The aggressive nature of
the MDA-MB-231 cancer model allowed us to analyze meta-
stasis to the brain, lung, liver, and bone (evident in untreated
Fig. 4 In vivo response of doxorubicin-loaded nanotubes in human orthotopic breast cancer. (a) Schematic diagram of the experimental approach
showing the timeline and description of the groups. (b) Tumor growth in mice either untreated (open circle), 80 µg of doxorubicin by intravenous
bolus injection (black circle), or doxorubicin-loaded nanotubes (standard dose 2 × 40 µg doxorubicin (open square) or high dose 2 × 80 μg of doxo-
rubicin close to the bilateral orthotopic tumors). (c) Primary tumor weights were assessed at the end of the study (week 6). (d) Representative cancer
cell-speciﬁc bioluminescence composite images at week 6. (e) Metastatic spread of cancer cells to organs at week 6. Statistical diﬀerences were
determined using ANOVA (see materials and methods) **P ≤ 0.01, ***P ≤ 0.001; error bars represent ±SEM for tumor growth and ±SD tumor
weights and are hidden in the plot-symbol when not visible, n = 4.
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control animals, Fig. 4e). Local treatment of primary breast
tumors with nanotubes loaded with the “standard” 40 μg doxo-
rubicin markedly reduced liver and lung metastases when
compared to i.v. dosed animals.
These studies demonstrate that using PEG nanotubes to
locally deliver doxorubicin to orthotopic breast tumors may be
more eﬀective in reducing tumor growth and metastasis. We
selected doxorubicin because it is a clinical relevant cytotoxic
agent which can be regarded as a benchmark therapeutic
payload allowing direct comparison with both pre-clinical and
clinically approved delivery systems.36 The physiochemical pro-
perties of doxorubicin are representative for many cytotoxic
anticancer agents and thus doxorubicin serves as a useful indi-
cator for other potential payloads. We note that sustained
doxorubicin exposure has been linked to drug resistance.37
However, we speculate that our delivery system would also be
applicable to other forms of cancer where local treatment is
desirable, for example neuroblastoma and glioblastoma.38 Due
to the versatile nature of the nanotube synthesis, and range of
acrylate monomers commercially available, there are a myriad
of ways that this platform technology can be built upon for
further investigations.
Conclusions
In summary, we show that poly(ethylene glycol) diacrylates as
well as their phosphate and Bisphenol derivatives can be
readily photopolymerized using anodized aluminum oxide
templates to control the size of the resulting nanotubes. All
synthesised nanotubes were flexible and approximately 2000
times softer than MWCNTs. The poly(ethylene glycol) nano-
tubes showed no toxicity in a panel of cell lines as well as
primary stem cells over a broad concentration range (IC50 >
120 μg ml−1). The PEG nanotubes could be readily loaded with
doxorubicin and subsequently release the drug for 42 days
in vitro (longest time tested). PEG nanotube mediated focal
delivery of doxorubicin to an orthotopic breast cancer mouse
model showed greater reduction in tumor growth, and aa
reduced metastasis rate, compared to a matching dose of doxo-
rubicin administered intravenously. The simple synthesis pro-
cedure and the range of monomers available for nanotube syn-
thesis means that a range of similar nanotubes can easily be
synthesized for applications in focal drug delivery or beyond.
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